43 results about "Renin–angiotensin system" patented technology

A method for treating congestive heart failure (CHF) has been developed that restores kidney renal functions by artificial vasodilation of at least one kidney. A vasodilator drug is locally delivered to the kidney via a kidney perfusion catheter. The drug can be mixed with the patient's blood, saline or other suitable solvent and the mixture directly applied to the kidney through the catheter. The restoration of kidney function assists the heart by removing excess fluid, urine and toxin from the patient, and by normalizing the patient's renin-angiotensin system and other neurohormonal substances. The method is applicable to treat chronic and acute CHF.

In one aspect, the present invention is directed to an apparatus and method for treating congestive heart failure that restores kidney renal functions by artificial perfusion of at least one kidney. In one aspect, a catheter inserted into the aorta of the patient has an outlet port that supplies the patient's blood obtained from a patient's aorta into an adjoining renal artery of the patient to perfuse the kidney. The catheter comprises a rotor housed inside a portion of the catheter to supply the blood to the kidney at a desired pressure. The restoration of kidney function assists the heart by removing excess fluid, urine and toxin from the patient, and by normalizing the patient's renin-angiotensin system and other neurohormonal substances.

A method for determining the levels of biomarkers, specifically, advanced glycation end products (AGEs) and oxidation products (Ops) in a biological sample such as a plasma ultrafiltrate, is used to determine a patient's risk and / or rate of developing diabetes related nephropathy. The preferred biomarkers to measure include Nε-(1-carboxyethyl-lysine (CEL), methylglyoxyl-derived hydroimidazolone (MGHI) and Nε-carboxymethyllysine (CML). Also provided herein is a method of diabetic care which includes determining a diabetic patient's risk of developing diabetes related kidney disease and adjusting the patient's treatment regimen to include in addition to glucose lowering agents, additional treatments such as medications that modify the renin-angiotensin system, or specialized diets with low levels of AGEs or oxidative products.

Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.

The invention provides an antihypertensive active rapeseed peptide and a preparation method and application thereof. The preparation method of the antihypertensive active rapeseed peptide includes obtaining crude extract of the antihypertensive active rapeseed peptide by pepsin and pancreatic enzymatic hydrolyzed rapeseed protein, and obtaining the antihypertensive active rapeseed peptide by refining. The invention further provides the antihypertensive active rapeseed peptide prepared by the method and application thereof. Sources of rapeseed meal for preparing the antihypertensive active rapeseed peptide are extensive, production process is simple, low in cost and environment-friendly, and the method is suitable for industrialization. The antihypertensive active rapeseed peptide causes low gastrointestinal reaction, is capable of resisting hydrolysis of human digestive enzymes, and has good antihypertensive effect by actively reacting to target organs. The antihypertensive active rapeseed peptide is capable of inhibiting not only ACE (angiotensin converting enzyme) but also renin activity, is capable of avoiding alternative pathways of a RAS (renin angiotensin system) activated by taking antihypertensive drug, ACE inhibitor, for long, and has bright application prospect in terms of lowering blood pressure.

The invention relates to application of patchouli alcohol in the preparation of drugs for prevention and treatment of renal injury and also provides a drug to antagonize renal fibrosis to prevent or / and treat hypertensive renal injury. The drug is mainly made from patchouli alcohol or patchouli oil, or with other drugs, as well as pharmaceutically acceptable accessories or accessory ingredients. The drug provided herein can inhibit renal fibrosis and retard renal injury by: inhibiting RAS (renin-angiotensin system), down-regulating TGF-beta 1 and PAI-1 levels, inhibiting the proliferation andactivation of MFB, reducing matrix protein synthesis and ECM (extracellular deposition) and improving pathogenic change in kidney tissue. Therefore, the patchouli alcohol based on renal fibrosis inhibition has excellent application prospect in the prevention or / and treatment renal injury, particularly in the development of drugs for hypertensive renal injury.

The invention provides an antihypertensive rapeseed peptide and a preparation method and an application of the antihypertensive rapeseed peptide. The method for preparing the antihypertensive rapeseed peptide includes using protease to hydrolyze a rapeseed protein water solution, then performing refining to obtain the antihypertensive rapeseed peptide. When the method for preparing the antihypertensive rapeseed peptide is compared with methods for preparing the antihypertensive rapeseed peptide in prior art, rapeseed meals or rapeseed isolated proteins are directly used as raw materials to obtain the antihypertensive rapeseed peptide by means of enzymatic hydrolysis, the sources of raw materials are wide, the production process is simple, the cost is low, the waste can be changed into the valuable, and environment protection is facilitated. The antihypertensive rapeseed peptide can be used for not only inhibiting angiotensin converting enzyme (ACE) activity, but also inhibiting renin activity to block an alternative pathway of a renin angiotensin system (RAS), the alternative pathway of the RAS is activated due to the fact that hypotensor of ACE inhibitor is taken for a long time, and the antihypertensive rapeseed peptide has a great developing prospect in decreasing blood pressure.

A method of treating a disease or condition in which up-regulating GAGs is therapeutically beneficial is disclosed. The method comprises locally administering to a subject a therapeutically effective amount of an agent capable of down-regulating activity or expression of a component of the renin-angiotensin system.

The invention provides methods of determining a diagnosis or prognosis of motor neuron disease in a mammal comprising determining the expression level of one or more proteins or polypeptides of the renin-angiotensin system in a sample taken from a subject. Similarly, aberrant post-translational modification of the proteins or polypeptides as compared to a negative control indicates a diagnosis of disease.

The instant invention relates to peptides obtained from the enzymatic hydrolysis of yellow pea seed proteins that are capable of lowering the blood pressure and reducing the effects of kidney disease in a subject b\ inhibiting or reducing the affinity of the enzymes in the renin-angiotensin system for their substrates, specifically renin, to compositions comprising said peptides and to uses thereof.

An inhibitor of the renin-angiotensin system is useful for the treatment or prevention of the lipodystrophy syndrome, e.g. in AIDS patients also receiving anti-retroviral therapy.

The present invention provides a novel approach to cancer diagnosis and therapy of cancer by providing compositions and methods for the identification and specific targeting of the cancer stem cell populations present in a tumour to eradicate, or slow or prevent tumour (5) growth and spread, including the potential for tumour metastasis, by modulation of the Renin-Angiotensin System including, but not limited to, Renin Receptor, Angiotensin II Receptor (2) and a secreted form of the Renin Receptor.

The present invention relates to cyclic indolizinecarboxamides and azaindolizinecarboxamides of the formulae Ia and Ib,wherein R, Ra, R10, R20, R30, R40, Y, n, p and q have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they inhibit the enzyme renin and modulate the activity of the renin-angiotensin system, and are useful for the treatment of diseases such as hypertension, for example. The invention furthermore relates to processes for the preparation of the compounds of the formulae Ia and Ib, their use and pharmaceutical compositions comprising them.

The invention provides establishment and application of an H-ras 12V transgenic male mouse liver tumor cell line MMHRL1. Specifically, the H-ras 12V transgenic male mouse liver tumor cell line MMHRL1 provided by the invention has stable properties, can be stably passed for a plurality of times, is applicable to establishment of a liver tumor animal model and is an ideal cell line for foundation and clinical prophase application researches of liver tumor. Furthermore, the H-ras 12V transgenic male mouse liver tumor cell line MMHRL1 can be used for expressing H-ras mutated cancer genes and has highly-activated Ras / MAPK (Renin-angiotensin system / Mitogen-activated Protein Kinase) and PI3K / AKT / mTOR (Phosphoinositide 3-kinase / protein kinase B / mammalian Target of Rapamycin) signal paths. The invention further provides the application of the cell line to the aspects of establishment of model animals, drug screening and the like.

The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an antioxidant compound for the treatment and / or prevention of cardiovascular disease.

An agent for enhancing therapeutic or prophylactic effect of administering an inhibitor of renin-angiotensin system, such as candesartan cilexetil, on renal diseases is disclosed. The agent comprises a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.

The present invention relates to a pharmaceutical composition comprising a. at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor, or b. at least one aspartyl aminopeptidase inhibitor and at least one chymase inhibitor. In an embodiment, the pharmaceutical composition comprises at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor and at least one chymase inhibitor. Furthermore, the invention relates to a pharmaceutical composition possessing inhibitory activity against a. aspartyl aminopeptidase and angiotensin-converting-enzyme (ACE), or b. against aspartyl aminopeptidase and chymase. In a third aspect, the invention relates to a kit of parts comprising a. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising an angiotensin-converting-enzyme (ACE) inhibitor, or b. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising a chymase inhibitor, or c. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising an angiotensin-converting-enzyme (ACE) inhibitor and a pharmaceutical composition comprising a chymase inhibitor. The invention also relates to a method for decreasing the blood pressure in a subject by administering a therapeutically effective amount of a pharmaceutical composition according to the invention to the subject. In another aspect, the invention relates to a method for treating a disease related to the RAS in a subject by administering a therapeutically effective amount of a pharmaceutical composition according to the invention to the subject.

The invention discloses a saurida elongata peptide with the function of reducing blood pressure. A method comprises steps as follows: step-by-step enzymolysis, isoelectric precipitation, second ultrafiltration, nanofiltration and freeze drying. Marine protease and land protease are adopted for synergetic enzymolysis, porphyra yezoensis protease is adopted firstly, a flavourzyme is adopted continuously on the basis, and the blood-pressure-reducing peptide with the functions of reducing blood pressure and protecting myocardial can be obtained. The saurida elongata peptide with the function of reducing blood pressure has the benefits as follows: the prepared blood-pressure-reducing peptide has the functions similar to those of GABA (gamma-aminobutyric acid), the blood pressure reducing function is related to an RAS (renin-angiotensin system), and the content of ANG-II (angiotensin II) in blood serum of a human body is reduced and the content of NO is increased if people take the saurida elongata peptide for a long time.

The invention provides a new application of enalapril to preparation of antitumor medicines. The enalapril can act on a renin angiotensin system (a regulator of a VEGF mediated angiogenesis system), and an ACE / AngII / AT1R route participating in adjusting cell proliferation and cell invasion. Treatment medicines can act on an ACE route participating in adjusting cell proliferation and invasion. Thetreatment manner not only can be used in the whole treatment period but also can be used for preventing cancer recurrence after treatment is successful. The use of the enalapril as an anticancer medicine also contributes to alleviating cardiovascular system side effects of conventional chemotherapy.

This invention relates to methods for treating renal diseases by using combination of prostaglandin E2 receptor antagonist and renin-angiotensin system inhibitor and pharmaceutical compositions for treating renal diseases comprising prostaglandin E2 receptor antagonist and renin-angiotensin system inhibitor.

It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.

The invention discloses a hypotensive extract, which contains rich gamma-aminobutyric acid. Seaweed is used as raw materials to obtain the hypotensive extract through freezing and thawing wall-breaking, salt precipitation and ultrafiltration purification. The hypotensive extract has the beneficial effects that ammonium sulfate and PEG4000 are added into supernate; the purity of the hypotensive extract is improved. The hypotensive extract obtained through extraction contains rich gamma-aminobutyric (GABA); after the eating, the activity of angiotensin I transferase (ACE) can be effectively inhibited; the content of angiotensin II in blood serum is reduced through lowering the conversion rate of the decapeptide angiotensin I, so that the blood pressure is reduced. The hypotensive extract provided by the invention lowers the blood pressure by regulating an RAS (Renin-angiotensin system); after the long-time eating, the content of the angiotensin II (ANG-II) in the human body blood serum is reduced; the NO content is increased.